Stock listing
LSE:0K16 Evolus, Inc. Common Stock Share Price
UK listing (LSE) of Evolus, Inc. Common Stock · home listing NASDAQ:EOLS
Follow Evolus, Inc. Common Stock into a list and get an email when it puts out news.
Home listing price · NASDAQ:EOLS
$6.52 USD -0.55 (-7.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:EOLS
- Day range
- $6.50 – $7.19 USDNov 20, 2026
- Volume
- 813,646 sharesNov 20, 2026
- Market cap
- $431.5M USDAt the close on Nov 20, 2026 · price × 66.19M shares outstanding
- 52-week range
- $3.86 – $9.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.07M USDMedian day 734,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EOLS · Home | $6.52 USD | -0.55 (-7.8%) | 813,646 | $6.79 | $7.19 | $6.50 | $7.07 | Close on Nov 20, 2026 |
| Frankfurt:EVL | €6.284 EUR | -0.182 (-2.8%) | — | €6.284 | €6.284 | €6.284 | €6.466 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EOLS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.52 | -0.55 | -7.8% | $6.79 | $7.19 | $6.50 | 813,646 | |
| $7.07 | +0.38 | +5.7% | $6.68 | $7.09 | $6.63 | 802,520 | |
| $6.69 | +0.06 | +0.9% | $6.61 | $6.72 | $6.30 | 670,639 | |
| $6.63 | -0.33 | -4.7% | $6.90 | $7.03 | $6.615 | 641,076 | |
| $6.96 | -0.22 | -3.1% | $7.18 | $7.18 | $6.85 | 455,367 | |
| $7.18 | -0.24 | -3.2% | $7.38 | $7.65 | $7.15 | 737,047 | |
| $7.42 | +0.61 | +9.0% | $6.86 | $7.44 | $6.85 | 1,287,320 | |
| $6.81 | -0.17 | -2.4% | $6.97 | $6.99 | $6.635 | 5,816,220 | |
| $6.98 | +0.175 | +2.6% | $6.88 | $7.04 | $6.72 | 1,150,207 | |
| $6.805 | +0.01 | +0.1% | $6.74 | $6.92 | $6.57 | 1,521,611 | |
| $6.795 | -0.675 | -9.0% | $6.64 | $7.27 | $6.412 | 2,128,693 | |
| $7.47 | +0.10 | +1.4% | $7.51 | $7.65 | $7.33 | 749,559 | |
| $7.37 | +0.21 | +2.9% | $7.17 | $7.415 | $7.17 | 440,561 | |
| $7.16 | -0.19 | -2.6% | $7.34 | $7.44 | $7.15 | 712,590 | |
| $7.35 | -0.17 | -2.3% | $7.48 | $7.56 | $7.24 | 793,582 | |
| $7.52 | -0.115 | -1.5% | $7.75 | $7.83 | $7.38 | 789,229 | |
| $7.635 | +0.265 | +3.6% | $7.38 | $7.705 | $7.30 | 671,393 | |
| $7.37 | +0.20 | +2.8% | $7.18 | $7.37 | $7.07 | 600,999 | |
| $7.17 | +0.16 | +2.3% | $7.06 | $7.19 | $6.90 | 430,106 | |
| $7.01 | -0.40 | -5.4% | $7.31 | $7.31 | $6.93 | 597,823 | |
| $7.41 | +0.01 | +0.1% | $7.39 | $7.625 | $7.30 | 621,862 | |
| $7.40 | +0.03 | +0.4% | $7.37 | $7.43 | $7.27 | 912,577 | |
| $7.37 | +0.01 | +0.1% | $7.38 | $7.63 | $7.335 | 447,832 | |
| $7.36 | +0.26 | +3.7% | $7.10 | $7.37 | $7.10 | 517,872 | |
| $7.10 | -0.47 | -6.2% | $7.61 | $7.61 | $7.015 | 761,700 | |
| $7.57 | +0.35 | +4.8% | $7.26 | $7.71 | $7.22 | 901,500 | |
| $7.22 | -0.29 | -3.9% | $7.42 | $7.60 | $7.205 | 1,007,600 | |
| $7.51 | -0.24 | -3.1% | $7.68 | $7.70 | $7.48 | 654,400 | |
| $7.75 | +0.02 | +0.3% | $7.76 | $7.83 | $7.67 | 1,002,200 | |
| $7.73 | -0.07 | -0.9% | $7.77 | $7.829 | $7.61 | 430,100 | |
| $7.80 | +0.06 | +0.8% | $7.68 | $7.805 | $7.535 | 1,078,000 | |
| $7.74 | +0.36 | +4.9% | $7.37 | $7.75 | $7.333 | 595,100 | |
| $7.38 | -0.09 | -1.2% | $7.47 | $7.56 | $7.16 | 663,900 | |
| $7.47 | +0.33 | +4.6% | $7.07 | $7.52 | $7.07 | 786,400 | |
| $7.14 | -0.55 | -7.2% | $7.72 | $7.72 | $6.913 | 2,070,900 | |
| $7.69 | -0.31 | -3.9% | $7.89 | $8.01 | $7.69 | 922,600 | |
| $8.00 | +0.01 | +0.1% | $7.97 | $8.15 | $7.87 | 624,400 | |
| $7.99 | +0.03 | +0.4% | $7.91 | $8.11 | $7.83 | 415,100 | |
| $7.96 | -0.01 | -0.1% | $7.90 | $8.075 | $7.805 | 478,200 | |
| $7.97 | +0.11 | +1.4% | $7.84 | $8.00 | $7.712 | 398,300 | |
| $7.86 | -0.14 | -1.7% | $7.96 | $8.00 | $7.79 | 363,000 | |
| $8.00 | -0.25 | -3.0% | $8.33 | $8.51 | $7.88 | 415,900 | |
| $8.25 | +0.26 | +3.3% | $8.10 | $8.265 | $8.00 | 500,700 | |
| $7.99 | +0.13 | +1.7% | $7.93 | $7.995 | $7.76 | 420,700 | |
| $7.86 | -0.15 | -1.9% | $8.00 | $8.00 | $7.805 | 1,181,600 | |
| $8.01 | +0.02 | +0.3% | $8.05 | $8.14 | $7.77 | 1,225,200 | |
| $7.99 | +0.08 | +1.0% | $7.93 | $8.09 | $7.82 | 683,400 | |
| $7.91 | -0.02 | -0.3% | $7.88 | $7.95 | $7.59 | 637,900 | |
| $7.93 | +0.09 | +1.1% | $7.90 | $8.25 | $7.87 | 515,600 | |
| $7.84 | -0.07 | -0.9% | $8.01 | $8.15 | $7.81 | 586,500 | |
| $7.91 | -0.66 | -7.7% | $8.43 | $8.45 | $7.75 | 1,211,700 | |
| $8.57 | -0.31 | -3.5% | $8.85 | $9.05 | $8.51 | 996,600 | |
| $8.88 | -0.42 | -4.5% | $9.00 | $9.12 | $8.751 | 1,727,700 | |
| $9.30 | +0.25 | +2.8% | $9.05 | $9.31 | $8.975 | 696,400 | |
| $9.05 | -0.01 | -0.1% | $9.08 | $9.10 | $8.91 | 734,200 | |
| $9.06 | -0.02 | -0.2% | $9.04 | $9.13 | $8.93 | 773,500 | |
| $9.08 | -0.01 | -0.1% | $9.04 | $9.124 | $8.93 | 594,000 | |
| $9.09 | +0.21 | +2.4% | $8.85 | $9.15 | $8.75 | 1,025,200 | |
| $8.88 | 0.00 | 0.0% | $8.84 | $8.94 | $8.595 | 1,059,300 | |
| $8.88 | +0.10 | +1.1% | $8.78 | $9.035 | $8.60 | 1,194,800 | |
| $8.78 | -0.195 | -2.2% | $8.86 | $9.08 | $8.77 | 1,512,800 | |
| $8.975 | +0.195 | +2.2% | $8.72 | $9.12 | $8.70 | 1,796,100 | |
| $8.78 | +0.39 | +4.6% | $8.39 | $8.82 | $8.26 | 1,320,200 | |
| $8.39 | +0.04 | +0.5% | $8.35 | $8.48 | $8.235 | 582,700 | |
| $8.35 | -0.25 | -2.9% | $8.55 | $8.55 | $8.32 | 663,000 |
- Ticker
- LSE:0K16
- Asset type
- Stock
- Exchange
- LSE
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest earnings call · Aug 5, 2026
Evolus, Inc. Common Stock (NASDAQ:EOLS) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 39 slides
Latest news
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 13, 2026
Closed $6.63 (-4.7%) on Nov 16, 2026
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook
Nov 4, 2026
Closed $6.80 (-9.0%) on Nov 5, 2026
Evolus to Participate in Upcoming Investor Conferences in New York and London
Oct 28, 2026
Closed $7.64 (+3.6%) on Oct 28, 2026
Evolus to Report Third Quarter Financial Results on November 4, 2026
Oct 21, 2026
Closed $7.40 (+0.4%) on Oct 21, 2026
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Oct 14, 2026
Closed $7.22 (-3.9%) on Oct 14, 2026
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Oct 1, 2026
Closed $7.69 (-3.9%) on Oct 1, 2026
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Aug 5, 2026
Closed $7.41 (+19.9%) on Aug 6, 2026
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Aug 4, 2026
Closed $6.12 (+1.2%) on Aug 4, 2026
Evolus to Report Second Quarter Financial Results on August 5, 2026
Jul 22, 2026
Closed $5.89 (+1.5%) on Jul 22, 2026
Evolus, Inc. Common Stock on 6ix
- News releases
- 21 in the last 12 months · 145 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 22 calls with a replay · 22 with a transcript · latest Aug 5, 2026
- Decks
- 17 decks · latest Nov 4, 2026
Where Evolus, Inc. Common Stock is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EOLS · Home listing | NASDAQ | United States | USD |
| gettex:EVL | gettex | Germany | EUR |
| Frankfurt:EVL | Frankfurt | Germany | EUR |
| LS Exchange:A2JDYX | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JDYX | Lang & Schwarz | Germany | EUR |
| BOATS:EOLS | BOATS | United States | USD |
| Tradegate:EVL | Tradegate | Germany | EUR |
| Dusseldorf:EVL | Dusseldorf | Germany | EUR |
| LSE:0K16 · This page | LSE | United Kingdom | USD |
| Munich:EVL | Munich | Germany | EUR |
| Stuttgart:EVL | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $546.7M USD
- P/E
- Loss
- EV/sales
- 1.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 66.4%
- Operating margin
- −4.8%
- Net margin
- −9.6%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.34
Forecasts
4 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.033 · 4 analysts
- Revenue, year to Dec 2026
- 334.3M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Moatazedi | President and Chief Executive Officer |
| Tatjana Mitchell | Chief Financial Officer |
| Jeff Plumer | General Counsel |
| Nareg Sagherian | Vice President, Head of Global Investor Relations and Corporate Communications |
| Jon Yerbury | Senior Vice President, Operations |
| Kourtney Cavallio | Senior Vice President, Marketing |
| Kurt Knab | Senior Vice President, Sales |
| Peter Kreymerman | Evolus VP & Head of Global Medical Affairs, Assistant Professor of Plastic Surgery at Campbell University |
| Umberto La Magna | Senior Vice President, Evolus International |
| Donna Lynne Colonna | Director of Medical Affairs, RN, BSN, Certified Nurse Injector, Certified Plastic Surgery Nurse |
| Jessica Novak | Chief People Officer |
| Meha Patel | Director of Medical Affairs, PA-C, MSPAS |
| Monica Champaneria | Evolus Medical Affairs Operations & Event Manager |
| Rui Avelar | Chief Medical Officer and Head of Research and Development |
Board
| Director | Role |
|---|---|
| David Moatazedi | President and Chief Executive Officer |
| Kourtney Cavallio | Senior Vice President, Marketing |
| Rui Avelar | Chief Medical Officer and Head of Research and Development |
| Tatjana Mitchell | Chief Financial Officer |
| Umberto La Magna | Senior Vice President, Evolus International |
Events
Calls
| Call | When | Status |
|---|---|---|
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q1 2026 Earnings Call | Mon, May 04, 2026 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q4 2025 Earnings Call | Tue, Mar 03, 2026 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q4 2024 Earnings Call | Tue, Mar 04, 2025 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q2 2024 Earnings Call | Wed, Jul 31, 2024 · 4:30 PM ET | Replay |
| Evolus, Inc. Common Stock (NASDAQ:EOLS) Q1 2024 Earnings Call | Tue, May 07, 2024 · 4:30 PM ET | Replay |
All 22 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −9.0% |
| Q2 2026 | Aug 5, 2026 · After close | +19.9% |
| Q1 2026 | May 4, 2026 · After close | +14.2% |
| Q4 2025 | Mar 3, 2026 | +30.3% |
| Q3 2025 | Nov 5, 2025 · After close | +5.4% |
| Q2 2025 | Aug 5, 2025 · After close | −28.5% |
| Q1 2025 | May 7, 2025 · After close | −14.2% |
| Q4 2024 | Mar 4, 2025 · After close | −1.3% |
| Q3 2024 | Nov 6, 2024 · After close | −15.0% |
| Q2 2024 | Jul 31, 2024 · After close | +13.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −1.2% |
| Q4 2023 | Mar 7, 2024 · After close | −4.9% |
| Q3 2023 | Nov 7, 2023 · After close | +8.2% |
| Q2 2023 | Aug 2, 2023 · After close | +2.1% |
| Q1 2023 | May 9, 2023 · After close | +16.0% |
| Q4 2022 | Mar 8, 2023 · After close | −3.2% |
| Q3 2022 | Nov 8, 2022 · After close | −9.1% |
| Q2 2022 | Aug 2, 2022 · Before open | −17.6% |
| Q1 2022 | May 10, 2022 · After close | +7.7% |
| Q4 2021 | Mar 3, 2022 · After close | +5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 39 slides | Nov 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 5, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 36 slides | May 4, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 36 slides | Mar 3, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 36 slides | Nov 5, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 37 slides | Mar 4, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 37 slides | Nov 6, 2024 |
| Investor Day (September 2024) | Investor day | 145 slides | Sep 12, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 34 slides | Jul 31, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 34 slides | May 7, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2023 Earnings Presentation | Earnings | 10 slides | Mar 7, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 19 slides | Nov 7, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 37 slides | Aug 2, 2023 |
| Technical Presentation (January 2023) | Technical | 23 slides | Jan 30, 2023 |
| Investor Presentation (January 2020) | Investor deck | 20 slides | Jan 10, 2020 |
| Investor Day (May 2019) | Investor day | 64 slides | May 8, 2019 |
| Investor Presentation (January 2019) | Investor deck | 21 slides | Jan 4, 2019 |
IPO
Priced at US$12.00 a share on Feb 7, 2018.
- Price
- US$12.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$60 million
- Underwriters' option
- Up to 750,000 more shares
- Listing
- EOLS on the Nasdaq Global Market
- Underwriters
- Cantor, Mizuho Securities, SunTrust Robinson Humphrey, JMP Securities · In the order on the cover
- Shares delivered
- On or about Feb 12, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 28, 2017 |
| Filed publicly | Jan 9, 2018 |
| Amended 3 times | Newest Feb 1, 2018 |
| Shares registered with an exchange | Feb 1, 2018 |
| Declared effective by the SEC | Feb 7, 2018 |
| Final prospectus, with the price | Feb 9, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 9, 2018 |
| EFFECT · Notice that a registration is effective | Feb 7, 2018 |
| CERT · Exchange's certificate of listing | Feb 5, 2018 |
| CORRESP · Letter to the SEC | Feb 5, 2018 |
| CORRESP · Letter to the SEC | Feb 5, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 1, 2018 |
| S-1/A · Registration statement, amended | Feb 1, 2018 |
| CORRESP · Letter to the SEC | Feb 1, 2018 |
| UPLOAD · Letter from the SEC | Jan 30, 2018 |
| S-1/A · Registration statement, amended | Jan 29, 2018 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 25, 2018 |
| S-1/A · Registration statement, amended | Jan 25, 2018 |
| UPLOAD · Letter from the SEC | Jan 17, 2018 |
| UPLOAD · Letter from the SEC | Jan 9, 2018 |
| S-1 · Registration statement | Jan 9, 2018 |
| CORRESP · Letter to the SEC | Jan 8, 2018 |
| DRSLTR · Letter to the SEC with a draft | Dec 20, 2017 |
| DRS/A · Draft registration statement, amended | Dec 20, 2017 |
| UPLOAD · Letter from the SEC | Dec 11, 2017 |
| DRS/A · Draft registration statement, amended | Nov 21, 2017 |
| DRSLTR · Letter to the SEC with a draft | Nov 21, 2017 |
| UPLOAD · Letter from the SEC | Sep 26, 2017 |
| DRS · Draft registration statement | Aug 28, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 9, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.2M | 266.3M | 202.1M | 148.6M | 99.7M | 56.5M | 34.9M | 0 | 0 | 0 |
| Cost of revenue | 100.1M | 84.0M | 64.5M | 58.8M | 43.5M | 18.3M | 8.01M | 0 | 218.0K | 326.0K |
| Gross profit | 197.1M | 182.3M | 137.6M | 89.8M | 56.1M | 38.2M | 26.9M | 0 | -218.0K | -326.0K |
| Research and development | 9.58M | 9.17M | 6.56M | 4.74M | 2.06M | 1.72M | 3.97M | 6.49M | 6.69M | 12.6M |
| Selling, general and administrative | 220.8M | 198.0M | 164.9M | 141.8M | 112.1M | 98.2M | 113.6M | 29.1M | 4.82M | 7.03M |
| Operating income | -32.7M | -34.4M | -49.2M | -65.3M | -44.4M | -153.1M | -98.9M | -46.1M | -11.7M | -20.0M |
| Depreciation and amortization | 7.51M | 5.30M | 5.13M | 3.72M | 5.62M | 7.03M | 4.13M | 9.00K | 218.0K | 326.0K |
| EBITDA | -25.2M | -29.1M | -44.1M | -61.6M | -38.8M | -146.0M | -94.8M | -46.1M | -11.5M | -19.6M |
| Interest expense | 19.7M | 18.7M | 13.8M | 9.10M | 1.40M | 10.5M | 7.95M | 863.0K | 5.00K | 0 |
| Income before tax | -51.0M | -49.8M | -61.5M | -74.3M | -46.8M | -162.9M | -105.1M | -46.8M | -11.7M | -20.0M |
| Income tax | 677.0K | 664.0K | 176.0K | 95.0K | 42.0K | 77.0K | -15.0M | 65.0K | -7.25M | 93.0K |
| Net income | -51.6M | -50.4M | -61.7M | -74.4M | -46.8M | -163.0M | -90.0M | -46.9M | -4.48M | -20.1M |
| Earnings per share, basic | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.27 | -1.08 |
| Earnings per share, diluted | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.27 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 53.8M | 87.0M | 62.8M | 53.9M | 146.3M | 102.6M | 109.9M | 93.2M | 0 | 187.0K |
| Short-term investments | 0 | 5.00M | 19.9M | 0 | 187.0K | |||||
| Receivables | 54.7M | 47.7M | 30.5M | 22.4M | 14.7M | 9.68M | 10.7M | 0 | 72.6M | |
| Inventory | 27.0M | 12.2M | 11.0M | 18.9M | 1.76M | 3.35M | 6.41M | 0 | ||
| Current assets | 142.9M | 151.3M | 112.4M | 100.8M | 178.8M | 127.6M | 152.2M | 94.3M | 72.8M | 211.0K |
| Property, plant and equipment | 5.37M | 3.22M | 2.09M | 2.62M | 1.37M | 1.30M | 902.0K | 0 | 0 | |
| Goodwill | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M | 21.2M |
| Total assets | 225.9M | 232.6M | 189.0M | 178.0M | 257.5M | 209.1M | 240.4M | 171.8M | 152.2M | 77.5M |
| Accounts payable | 23.4M | 9.24M | 4.27M | 8.94M | 6.09M | 9.62M | 5.80M | 1.56M | 445.0K | 2.88M |
| Current liabilities | 75.3M | 63.0M | 48.3M | 46.5M | 57.7M | 180.2M | 24.4M | 5.28M | 212.7M | 63.3M |
| Long-term debt | 146.1M | 121.5M | 120.4M | 71.9M | 71.2M | 40.5M | 73.5M | 0 | ||
| Total debt | 146.1M | 121.5M | 120.4M | 71.9M | 71.2M | 138.3M | 73.5M | 0 | 211.3M | 59.8M |
| Total liabilities | 249.0M | 227.0M | 209.7M | 159.5M | 175.6M | 282.0M | 161.0M | 87.5M | 227.8M | 84.6M |
| Shareholders' equity | -23.1M | 5.52M | -20.7M | 18.5M | 81.9M | -73.0M | 79.5M | 84.4M | -75.5M | -7.11M |
| Shares outstanding | 65.0M | 63.5M | 57.8M | 56.3M | 55.6M | 33.7M | 33.6M | 27.3M | 16.5M | 18.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -42.3M | -18.0M | -34.0M | -84.9M | -33.4M | -57.9M | -93.4M | -25.7M | -13.2M | -13.3M |
| Capital spending | -3.44M | -1.47M | -473.0K | -1.62M | -393.0K | -815.0K | -345.0K | -9.00K | 0 | -9.00K |
| Free cash flow | -45.7M | -19.5M | -34.5M | -86.5M | -33.8M | -58.7M | -93.7M | -25.7M | -13.2M | -13.3M |
| Cash from investing | -8.45M | -4.82M | -1.63M | -2.94M | 4.03M | 12.2M | -23.4M | -9.00K | 0 | -9.00K |
| Cash from financing | 17.3M | 47.4M | 44.6M | -4.15M | 73.1M | 38.3M | 133.5M | 118.8M | 13.0M | 13.3M |
| Share buybacks | 103.1M | 73.1M | -239.0K | -1.29M | -1.29M | |||||
| Change in cash | -33.1M | 24.1M | 8.92M | -92.3M | 43.7M | -7.33M | 16.7M | 93.2M | -187.0K | -187.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 9, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 31, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 8-K · Current report | Aug 4, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 8, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Jun 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Jun 10, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Management or board change | SEC |
| 8-K · Current report | May 27, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 8-K · Current report | May 5, 2025 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 21, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 18, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 12, 2024 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 11, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 11, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 7, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 16, 2024 | Results | SEC |
| 8-K · Current report | Dec 20, 2023 | Material contract | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 6, 2023 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 27, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 18, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 18, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Oct 6, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 4, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2023 | Results | SEC |
| 8-K · Current report | Jul 27, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Jun 16, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jun 14, 2023 | Meeting outcome | SEC |
| 424B5 · Prospectus | Jun 9, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 9, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 7, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jun 7, 2023 | Offer document | SEC |
This page holds 200 of 558 filings. Open Filings
Cap table
Built by 6ix from Evolus, Inc. Common Stock’s releases · as of Oct 30, 2026
- Common shares
- 66,188,366
- Fully diluted
- 66,382,701
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 66,188,366 | Oct 30, 2026 |
| Options and RSUs | 194,335 |
Warrants and options
| Lot |
|---|
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 66,188,366 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Gill Other companies: Telix Pharmaceuticals Limited (Chair & Independent Non-Executive Director · Since Apr 2, 2026); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past) | Director · Since at least Feb 12, 2018 |
| Lauren P. Silvernail Other companies: Dynavax Technologies Corporation (Director · Since at least Feb 3, 2025); Harrow, Inc. (Member, Board of Directors, Independent Director · Since at least Jan 26, 2024); Harpoon Therapeutics Inc (Director · Sep 15, 2022 – Mar 11, 2024 · Past); Revance Therapeutics, Inc. (CFO & CBO · Feb 5, 2014 – May 22, 2018 · Past); Ista Pharmaceuticals Inc (CFO & VP Corporate Development · Feb 16, 2006 – Jun 6, 2012 · Past) | See Remarks · May 29, 2018 – May 17, 2022 · Past |
| Karah Parschauer Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Dec 22, 2021); Ultragenyx Pharmaceutical Inc. (EVP and Chief Legal Officer · Since at least Jun 20, 2016); Anebulo Pharmaceuticals, Inc. (Director · May 6, 2021 – Apr 21, 2022 · Past); Arcturus Therapeutics Holdings Inc. (Director · Jun 19, 2019 – Jun 18, 2021 · Past) | Director · Since at least Jul 15, 2019 |
| Bosun Hau Other companies: Exicure, Inc. (Director · Aug 2, 2019 – Jun 2, 2021 · Past); Bicycle Therapeutics PLC (Director · May 22, 2019 – May 22, 2019 · Past); Cellular Biomedicine Group Inc (Director · Feb 6, 2018 – May 18, 2018 · Past) | Director · Feb 7, 2018 – Jan 23, 2020 · Past |
| Peter C Farrell Other companies: Arcturus Therapeutics Holdings Inc. (Director · Since at least Jan 1, 2019); ResMed Inc. (Director · Since at least Apr 2, 2007); NuVasive Inc (Director · May 24, 2007 – May 3, 2018 · Past) | Director · Jul 15, 2019 – Jan 27, 2023 · Past |
| David Moatazedi Other companies: Biomerica, Inc. (President and Chief Executive Officer · Since at least Dec 7, 2022); Vyome Holdings, Inc. (Director · Mar 13, 2017 – Jul 23, 2019 · Past) | President and Chief Executive Officer · Since at least May 6, 2018 |
| Albert G White III Other companies: The Cooper Companies, Inc. (President & CEO, Director · Since at least Apr 10, 2006) | Director · Since at least Jul 1, 2024 |
| Crystal Muilenburg Other companies: PMGC Holdings Inc. (Director · Nov 13, 2023 – Nov 13, 2023 · Past) | Chief Marketing Officer · Feb 25, 2021 – Mar 8, 2022 · Past |
| Michael M Jafar Other companies: Desktop Metal Inc (CEO, DESKTOP HEALTH · Aug 11, 2021 – Jun 1, 2022 · Past) | See Remarks · Jun 18, 2018 – Jan 27, 2021 · Past |
| Murthy V Simhambhatla Other companies: Abbott Laboratories (Senior Vice President · Jan 1, 2013 – Feb 27, 2015 · Past) | See Remarks, Director · Feb 7, 2018 – Feb 7, 2018 · Past |
All 31 people
| Person | Seat |
|---|---|
| Rui Avelar Other companies: Angiotech Pharmaceuticals Inc (Chief Medical Officer · Mar 31, 2008 – Mar 8, 2010 · Past) | Chief Medical Officer and Head of Research and Development · Since at least Feb 7, 2018 |
| Sandra Beaver Other companies: Tandem Diabetes Care, Inc. (Director · Since at least Nov 7, 2025) | Chief Financial Officer · Sep 5, 2022 – May 13, 2025 · Past |
| Simone Blank Other companies: Sirona Dental Systems Inc (Executive VP and CFO, Director · Jun 20, 2006 – Dec 8, 2012 · Past) | Director · Feb 7, 2018 – Mar 7, 2025 · Past |
| Vikram Malik Other companies: AEON Biopharma, Inc. (President, Director · Feb 8, 2021 – Feb 8, 2021 · Past) | Director · Since at least Feb 7, 2018 |
| Brady Stewart | Director · Since at least Jan 5, 2022 |
| Donna Lynne Colonna | Director of Medical Affairs, RN, BSN, Certified Nurse Injector, Certified Plastic Surgery Nurse · Since at least Nov 5, 2026 |
| J Christopher Marmo | Chief Operating Officer · Feb 7, 2018 – Feb 7, 2018 · Past |
| Jeff Plumer | General Counsel · Since at least Nov 4, 2026 |
| Jessica Novak | Chief People Officer · Since at least Nov 4, 2026 |
| Jon Yerbury | Senior Vice President, Operations · Since at least Nov 4, 2026 |
| Kourtney Cavallio | Senior Vice President, Marketing · Since at least Nov 5, 2026 |
| Kristine Romine | Director · Feb 7, 2018 – Jan 23, 2020 · Past |
| Kurt Knab | Senior Vice President, Sales · Since at least Nov 4, 2026 |
| Meha Patel | Director of Medical Affairs, PA-C, MSPAS · Since at least Nov 5, 2026 |
| Monica Champaneria | Evolus Medical Affairs Operations & Event Manager · Since at least Nov 5, 2026 |
| Nareg Sagherian | Vice President, Head of Global Investor Relations and Corporate Communications · Since at least Oct 1, 2026 |
| Peter Kreymerman | Evolus VP & Head of Global Medical Affairs, Assistant Professor of Plastic Surgery at Campbell University · Since at least Nov 5, 2026 |
| Robert Hayman | Director · Feb 7, 2018 – Feb 7, 2024 · Past |
| Tatjana Mitchell | Chief Financial Officer · Since at least Sep 8, 2025 |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer · Since at least Aug 21, 2023 |
| Umberto La Magna | Senior Vice President, Evolus International · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Evolus, Inc. Common Stock.